Human cathelicidin LL-37 prevents bacterial biofilm formation

Future Medicinal Chemistry

Volumn 4, Issue 12, 2012, Pages 1587-1599

  Jacobsen, Andreas S ^a   Jenssen, Håvard ^a  

^a ROSKILDE UNIVERSITY   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

CATHELICIDIN ANTIMICROBIAL PEPTIDE LL 37;

BACTERIAL INFECTION; BACTERICIDAL ACTIVITY; BIOFILM; DRUG EFFECT; DRUG MECHANISM; HUMAN; IMMUNE RESPONSE; IMMUNOMODULATION; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW;

ADJUVANTS, IMMUNOLOGIC; ANTI-INFECTIVE AGENTS; ANTIMICROBIAL CATIONIC PEPTIDES; BIOFILMS; GRAM-NEGATIVE BACTERIA; GRAM-POSITIVE BACTERIA; HUMANS;

EID: 84865479024     PISSN: 17568919     EISSN: 17568927     Source Type: Journal    
DOI: 10.4155/fmc.12.97     Document Type: Review

References (149)

1. Hoiby N, Ciofu O, Johansen HK et al. The clinical impact of bacterial biofilms. Int. J. Oral Sci. 3(2), 55-65 (2011).
2. Costerton JW, Stewart PS, Greenberg EP. Bacterial biofilms: a common cause of persistent infections. Science 284(5418), 1318-1322 (1999). (Pubitemid 29289651)
3. Vuong C, Otto M. Staphylococcus epidermidis infections. Microbes Infect. 4(4), 481-489 (2002). (Pubitemid 34270685)
4. Riordan JR, Rommens JM, Kerem B et al. Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA. Science 245(4922), 1066-1073 (1989). (Pubitemid 19231814)
5. Welsh MJ, Smith AE. Molecular mechanisms of CFTR chloride channel dysfunction in cystic fibrosis. Cell 73(7), 1251-1254 (1993). (Pubitemid 23201140)
6. Boucher RC. New concepts of the pathogenesis of cystic fibrosis lung disease. Eur. Respir. J. 23(1), 146-158 (2004). (Pubitemid 38088512)
7. Regnis JA, Robinson M, Bailey DL et al. Mucociliary clearance in patients with cystic fibrosis and in normal subjects. Am. J. Respir. Crit. Care Med. 150(1), 66-71 (1994). (Pubitemid 24209938)
8. Lyczak JB, Cannon CL, Pier GB. Lung infections associated with cystic fibrosis. Clin. Microbiol. Rev. 15(2), 194-222 (2002). (Pubitemid 34303763)
9. Hart CA, Winstanley C. Persistent and aggressive bacteria in the lungs of cystic fibrosis children. Br. Med. Bull. 61, 81-96 (2002). (Pubitemid 34477557)
10. Matsui H, Grubb BR, Tarran R et al. Evidence for periciliary liquid layer depletion, not abnormal ion composition, in the pathogenesis of cystic fibrosis airways disease. Cell 95(7), 1005-1015 (1998). (Pubitemid 29019052)
11. Chace KV, Flux M, Sachdev GP. Comparison of physicochemical properties of purified mucus glycoproteins isolated from respiratory secretions of cystic fibrosis and asthmatic patients. Biochemistry 24(25), 7334-7341 (1985). (Pubitemid 16165349)
12. Worlitzsch D, Tarran R, Ulrich M et al. Effects of reduced mucus oxygen concentration in airway Pseudomonas infections of cystic fibrosis patients. J. Clin. Invest. 109(3), 317-325 (2002). (Pubitemid 34141805)
13. Bjarnsholt T, Jensen PO, Fiandaca MJ et al. Pseudomonas aeruginosa biofilms in the respiratory tract of cystic fibrosis patients. Pediatr. Pulmonol. 44(6), 547-558 (2009).
14. Flemming HC, Wingender J. The biofilm matrix. Nat. Rev. Microbiol. 8(9), 623-633 (2010).
15. Hoiby N, Ciofu O, Bjarnsholt T. Pseudomonas aeruginosa biofilms in cystic fibrosis. Fut. Microbiol. 5(11), 1663-1674 (2010).
16. Hoiby N. Pseudomonas aeruginosa infection in cystic-fibrosis - relationship between mucoid strains of Pseudomonas aeruginosa and humoral immune-response. Acta Pathol. Microbiol. Scand. B Microbiol. Immunol. 82(4), 551-558 (1974).
17. Pedersen SS, Hoiby N, Espersen F, Koch C. Role of alginate in infection with mucoid Pseudomonas aeruginosa in cystic fibrosis. Thorax 47(1), 6-13 (1992).
18. Hoiby N, Krogh Johansen H, Moser C, Song Z, Ciofu O, Kharazmi A. Pseudomonas aeruginosa and the in vitro and in vivo biofilm mode of growth. Microbes Infect. 3(1), 23-35 (2001). (Pubitemid 32172037)
19. Hancock RE, Speert DP. Antibiotic resistance in Pseudomonas aeruginosa: mechanisms and impact on treatment. Drug Resist. Updat. 3(4), 247-255 (2000).
20. Vuong C, Voyich JM, Fischer ER et al. Polysaccharide intercellular adhesin (PIA) protects Staphylococcus epidermidis against major components of the human innate immune system. Cell Microbiol. 6(3), 269-275 (2004). (Pubitemid 38248010)
21. Benincasa M, Mattiuzzo M, Herasimenka Y, Cescutti P, Rizzo R, Gennaro R. Activity of antimicrobial peptides in the presence of polysaccharides produced by pulmonary pathogens. J. Pept. Sci. 15(9), 595-600 (2009).
22. Kai-Larsen Y, Luthje P, Chromek M et al. Uropathogenic Escherichia coli modulates immune responses and its curli fimbriae Executive summary.. Human cathelicidin LL-37 is a multifunctional peptide and the only described cathelicidin found in humans... Antimicrobial effects of LL-37 have been shown against a range of bacteria, virus and fungi, although recently the immune stimulatory effects of LL-37 have been argued to be the most prominent and important biological function for this peptide... LL-37 prevents biofilm formation at sub-inhibitory concentrations, which assists the human defence system in its constant struggle against bacterial infections... The use of LL-37 and LL-37-derived peptides could be of tremendous value in controlling and reducing biofilm development in multiple clinical settings... Future perspectives indicate the promising effects of LL-37 and LL-37-derived peptides in therapy, as peptides with lower toxicity, lower production cost, higher stability and retained antibiofilm efficacy have been designed. However, understanding how these peptides control biofilm development is essential for driving this research one step further and delivering novel potent antibiofilm peptide candidates for clinical testing. interact with the antimicrobial peptide LL-37. PLoS Pathog. 6(7), E1001010 (2010). Demonstrates that LL-37 can inhibit curli-mediated biofilm formation in uropathogenic Escherichia coli.
23. De Smet K, Contreras R. Human antimicrobial peptides: defensins, cathelicidins and histatins. Biotechnol. Lett. 27(18), 1337-1347 (2005). Overview of the antibacterial activity of LL-37 against a variety of different clinical and commercially available strains. (Pubitemid 41805626)
24. Zanetti M, Gennaro R, Romeo D. Cathelicidins: a novel protein family with a common proregion and a variable C-terminal antimicrobial domain. FEBS Lett. 374(1), 1-5 (1995).
25. Durr UH, Sudheendra US, Ramamoorthy A. LL-37, the only human member of the cathelicidin family of antimicrobial peptides. Biochim. Biophys. Acta 1758(9), 1408-1425 (2006). (Pubitemid 44436081)
26. Larrick JW, Lee J, Ma S et al. Structural, functional analysis and localization of the human CAP18 gene. FEBS Lett. 398(1), 74-80 (1996). (Pubitemid 26400345)
27. Gudmundsson GH, Agerberth B, Odeberg J, Bergman T, Olsson B, Salcedo R. The human gene FALL39 and processing of the cathelin precursor to the antibacterial peptide LL-37 in granulocytes. Eur. J. Biochem. 238(2), 325-332 (1996). (Pubitemid 26188246)
28. Wang G. Structures of human host defense cathelicidin LL-37 and its smallest antimicrobial peptide KR-12 in lipid micelles. J. Biol. Chem. 283(47), 32637-32643 (2008).
29. Oren Z, Lerman JC, Gudmundsson GH, Agerberth B, Shai Y. Structure and organization of the human antimicrobial peptide LL-37 in phospholipid membranes: relevance to the molecular basis for its non-cell-selective activity. Biochem. J. 341(Pt 3), 501-513 (1999). (Pubitemid 29389178)
30. Larrick JW, Hirata M, Zhong J, Wright SC. Anti-microbial activity of human CAP18 peptides. Immunotechnology 1(1), 65-72 (1995).
31. Larrick JW, Hirata M, Balint RF, Lee J, Zhong J, Wright SC. Human CAP18: a novel antimicrobial lipopolysaccharide-binding protein. Infect. Immun. 63(4), 1291-1297 (1995).
32. Nagaoka I, Hirota S, Niyonsaba F et al. Cathelicidin family of antibacterial peptides CAP18 and CAP11 inhibit the expression of TNF-a by blocking the binding of LPS to CD14 (+) cells. J. Immunol. 167(6), 3329-3338 (2001). (Pubitemid 32852575)
33. Agerberth B, Charo J, Werr J et al. The human antimicrobial and chemotactic peptides LL-37 and α-defensins are expressed by specific lymphocyte and monocyte populations. Blood 96(9), 3086-3093 (2000).
34. Di Nardo A, Vitiello A, Gallo RL. Cutting edge: mast cell antimicrobial activity is mediated by expression of cathelicidin antimicrobial peptide. J. Immunol. 170(5), 2274-2278 (2003). (Pubitemid 36245611)
35. Cowland JB, Johnsen AH, Borregaard N. hCAP-18, a cathelin/pro-bactenecin- like protein of human neutrophil specific granules. FEBS Lett. 368(1), 173-176 (1995).
36. Sorensen OE, Follin P, Johnsen AH et al. Human cathelicidin, hCAP-18, is processed to the antimicrobial peptide LL-37 by extracellular cleavage with proteinase 3. Blood 97(12), 3951-3959 (2001).
37. Hase K, Eckmann L, Leopard JD, Varki N, Kagnoff MF. Cell differentiation is a key determinant of cathelicidin LL-37/human cationic antimicrobial protein 18 expression by human colon epithelium. Infect. Immun. 70(2), 953-963 (2002). (Pubitemid 34083859)
38. Hase K, Murakami M, Iimura M et al. Expression of LL-37 by human gastric epithelial cells as a potential host defense mechanism against Helicobacter pylori. Gastroenterology 125(6), 1613-1625 (2003). (Pubitemid 37500425)
39. Chromek M, Slamova Z, Bergman P et al. The antimicrobial peptide cathelicidin protects the urinary tract against invasive bacterial infection. Nat. Med. 12(6), 636-641 (2006). (Pubitemid 43865231)
40. Malm J, Sorensen O, Persson T et al. The human cationic antimicrobial protein (hCAP-18) is expressed in the epithelium of human epididymis, is present in seminal plasma at high concentrations, and is attached to spermatozoa. Infect. Immun. 68(7), 4297-4302 (2000). (Pubitemid 30434586)
41. Bals R, Wang X, Zasloff M, Wilson JM. The peptide antibiotic LL-37/hCAP-18 is expressed in epithelia of the human lung where it has broad antimicrobial activity at the airway surface. Proc. Natl Acad. Sci. USA 95(16), 9541-9546 (1998). (Pubitemid 28506267)
42. Agerberth B, Gunne H, Odeberg J, Kogner P, Boman HG, Gudmundsson GH. FALL-39, a putative human peptide antibiotic, is cysteinefree and expressed in bone marrow and testis. Proc. Natl Acad. Sci. USA 92(1), 195-199 (1995).
43. Andersson E, Sorensen OE, Frohm B, Borregaard N, Egesten A, Malm J. Isolation of human cationic antimicrobial protein-18 from seminal plasma and its association with prostasomes. Hum. Reprod. 17(10), 2529-2534 (2002). (Pubitemid 35174098)
44. Frohm M, Gunne H, Bergman AC et al. Biochemical and antibacterial analysis of human wound and blister fluid. Eur. J. Biochem. 237(1), 86-92 (1996). (Pubitemid 26110276)
45. Murakami M, Ohtake T, Dorschner RA, Schittek B, Garbe C, Gallo RL. Cathelicidin anti-microbial peptide expression in sweat, an innate defense system for the skin. J. Invest. Dermatol. 119(5), 1090-1095 (2002). (Pubitemid 35434172)
46. Yamasaki K, Schauber J, Coda A et al. Kallikrein-mediated proteolysis regulates the antimicrobial effects of cathelicidins in skin. FASEB J. 20(12), 2068-2080 (2006). (Pubitemid 44953906)
47. Murakami M, Ohtake T, Dorschner RA, Gallo RL. Cathelicidin antimicrobial peptides are expressed in salivary glands and saliva. J. Dent. Res. 81(12), 845-850 (2002).
48. Davidopoulou S, Diza E, Menexes G, Kalfas S. Salivary concentration of the antimicrobial peptide LL-37 in children. Arch. Oral Biol. (2012).
49. Sorensen OE, Gram L, Johnsen AH et al. Processing of seminal plasma hCAP-18 to ALL-38 by gastricsin: a novel mechanism of generating antimicrobial peptides in vagina. J. Biol. Chem. 278(31), 28540-28546 (2003). (Pubitemid 36935758)
50. Murakami M, Lopez-Garcia B, Braff M, Dorschner RA, Gallo RL. Postsecretory processing generates multiple cathelicidins for enhanced topical antimicrobial defense. J. Immunol. 172(5), 3070-3077 (2004). The first in a series of papers demonstrating that postsecratory processing of human cathelicidin may lead to new more potent derivatives of the well-described active peptide LL-37, thus adding an additional layer of complexity to the human biology and defence strategies. (Pubitemid 38263696)
51. Amer LS, Bishop BM, Van Hoek ML. Antimicrobial and antibiofilm activity of cathelicidins and short, synthetic peptides against Francisella. Biochem. Biophys. Res. Commun. 396(2), 246-251 (2010).
52. Sharpe SW, Kuehn MJ, Mason KM. Elicitation of epithelial cell-derived immune effectors by outer membrane vesicles of nontypeable Haemophilus influenzae. Infect. Immun. 79(11), 4361-4369 (2011).
53. Raqib R, Sarker P, Bergman P et al. Improved outcome in shigellosis associated with butyrate induction of an endogenous peptide antibiotic. Proc. Natl Acad. Sci. USA 103(24), 9178-9183 (2006). (Pubitemid 43902552)
54. Schauber J, Iffland K, Frisch S et al. Histone-deacetylase inhibitors induce the cathelicidin LL-37 in gastrointestinal cells. Mol. Immunol. 41(9), 847-854 (2004). (Pubitemid 38903168)
55. Kida Y, Shimizu T, Kuwano K. Sodium butyrate up-regulates cathelicidin gene expression via activator protein-1 and histone acetylation at the promoter region in a human lung epithelial cell line, EBC-1. Mol. Immunol. 43(12), 1972-1981 (2006).
56. Termen S, Tollin M, Rodriguez E et al. PU.1 and bacterial metabolites regulate the human gene CAMP encoding antimicrobial peptide LL-37 in colon epithelial cells. Mol. Immunol. 45(15), 3947-3955 (2008).
57. Wu H, Zhang G, Minton JE, Ross CR, Blecha F. Regulation of cathelicidin gene expression: induction by lipopolysaccharide, interleukin-6, retinoic acid, and Salmonella enterica serovar typhimurium infection. Infect. Immun. 68(10), 5552-5558 (2000).
58. Gombart AF, Bhan I, Borregaard N et al. Low plasma level of cathelicidin antimicrobial peptide (hCAP18) predicts increased infectious disease mortality in patients undergoing hemodialysis. Clin. Infect. Dis. 48(4), 418-424 (2009).
59. Heilborn JD, Nilsson MF, Kratz G et al. The cathelicidin anti-microbial peptide LL-37 is involved in re-epithelialization of human skin wounds and is lacking in chronic ulcer epithelium. J. Invest. Dermatol. 120(3), 379-389 (2003). (Pubitemid 36298423)
60. Putsep K, Carlsson G, Boman HG, Andersson M. Deficiency of antibacterial peptides in patients with Morbus Kostmann: an observation study. Lancet 360(9340), 1144-1149 (2002). (Pubitemid 35246490)
61. Yamasaki K, Di Nardo A, Bardan A et al. Increased serine protease activity and cathelicidin promotes skin inflammation in rosacea. Nat. Med. 13(8), 975-980 (2007). (Pubitemid 47222043)
62. Frohm M, Agerberth B, Ahangari G et al. The expression of the gene coding for the antibacterial peptide LL-37 is induced in human keratinocytes during inflammatory disorders. J. Biol. Chem. 272(24), 15258-15263 (1997). (Pubitemid 27255544)
63. Kim JE, Kim BJ, Jeong MS et al. Expression and modulation of LL-37 in normal human keratinocytes, HaCaT cells, and inflammatory skin diseases. J. Korean Med. Sci. 20(4), 649-654 (2005).
64. Kim ST, Cha HE, Kim DY et al. Antimicrobial peptide LL-37 is upregulated in chronic nasal inflammatory disease. Acta Otolaryngol. 123(1), 81-85 (2003). (Pubitemid 36216517)
65. Heilborn JD, Nilsson MF, Jimenez CI et al. Antimicrobial protein hCAP18/LL-37 is highly expressed in breast cancer and is a putative growth factor for epithelial cells. Int. J. Cancer 114(5), 713-719 (2005). (Pubitemid 40344432)
66. Huang LC, Petkova TD, Reins RY, Proske RJ, Mcdermott AM. Multifunctional roles of human cathelicidin (LL-37) at the ocular surface. Invest. Ophthalmol. Vis. Sci. 47(6), 2369-2380 (2006). (Pubitemid 351639817)
67. Tanaka D, Miyasaki KT, Lehrer RI. Sensitivity of Actinobacillus actinomycetemcomitans and Capnocytophaga spp. to the bactericidal action of LL-37: a cathelicidin found in human leukocytes and epithelium. Oral Microbiol. Immunol. 15(4), 226-231 (2000). (Pubitemid 30466488)
68. Dorschner RA, Pestonjamasp VK, Tamakuwala S et al. Cutaneous injury induces the release of cathelicidin antimicrobial peptides active against group A Streptococcus. J. Invest. Dermatol. 117(1), 91-97 (2001). (Pubitemid 32652444)
69. Turner J, Cho Y, Dinh NN, Waring AJ, Lehrer RI. Activities of LL-37, a cathelin-associated antimicrobial peptide of human neutrophils. Antimicrob. Agents Chemother. 42(9), 2206-2214 (1998). (Pubitemid 28420351)
70. Turkoglu O, Kandiloglu G, Berdeli A, Emingil G, Atilla G. Antimicrobial peptide hCAP-18/LL-37 protein and mRNA expressions in different periodontal diseases. Oral Dis. 17(1), 60-67 (2011).
71. Dong F, Hoefsloot LH, Schelen AM et al. Identification of a nonsense mutation in the granulocyte-colony-stimulating factor receptor in severe congenital neutropenia. Proc. Natl Acad. Sci. USA 91(10), 4480-4484 (1994).
72. Carlsson G, Andersson M, Putsep K et al. Kostmann syndrome or infantile genetic agranulocytosis, part one: celebrating 50 years of clinical and basic research on severe congenital neutropenia. Acta Paediatr. 95(12), 1526-1532 (2006). (Pubitemid 44863801)
73. Woo JS, Jeong JY, Hwang YJ, Chae SW, Hwang SJ, Lee HM. Expression of cathelicidin in human salivary glands. Arch. Otolaryngol. Head Neck Surg. 129(2), 211-214 (2003). (Pubitemid 36222570)
74. Song JJ, Hwang KS, Woo JS et al. Expression of cathelicidin in recurrent throat infection. Int. J. Pediatr. Otorhinolaryngol. 70(3), 487-492 (2006). (Pubitemid 43155193)
75. Tao R, Jurevic RJ, Coulton KK et al. Salivary antimicrobial peptide expression and dental caries experience in children. Antimicrob. Agents Chemother. 49(9), 3883-3888 (2005). (Pubitemid 41233045)
76. Altman H, Steinberg D, Porat Y et al. In vitro assessment of antimicrobial peptides as potential agents against several oral bacteria. J. Antimicrob. Chemother. 58(1), 198-201 (2006). (Pubitemid 44295008)
77. Ji S, Hyun J, Park E, Lee BL, Kim KK, Choi Y. Susceptibility of various oral bacteria to antimicrobial peptides and to phagocytosis by neutrophils. J. Periodontal. Res. 42(5), 410-419 (2007).
78. Ouhara K, Komatsuzawa H, Yamada S et al. Susceptibilities of periodontopathogenic and cariogenic bacteria to antibacterial peptides, {b}-defensins and LL37, produced by human epithelial cells. J. Antimicrob. Chemother. 55(6), 888-896 (2005). (Pubitemid 40883173)
79. Johansson J, Gudmundsson GH, Rottenberg ME, Berndt KD, Agerberth B. Conformation-dependent antibacterial activity of the naturally occurring human peptide LL-37. J. Biol. Chem. 273(6), 3718-3724 (1998). (Pubitemid 28109800)
80. Kandasamy SK, Larson RG. Effect of salt on the interactions of antimicrobial peptides with zwitterionic lipid bilayers. Biochim. Biophys. Acta 1758(9), 1274-1284 (2006). (Pubitemid 44436074)
81. Neyraud E, Prinz J, Dransfield E. NaCl and sugar release, salivation and taste during mastication of salted chewing gum. Physiol. Behav. 79(4-5), 731-737 (2003). (Pubitemid 37087968)
82. Den Hertog AL, Van Marle J, Van Veen HA et al. Candidacidal effects of two antimicrobial peptides: histatin 5 causes small membrane defects, but LL-37 causes massive disruption of the cell membrane. Biochem. J. 388(Pt 2), 689-695 (2005). (Pubitemid 40839946)
83. Lopez-Garcia B, Lee PH, Yamasaki K, Gallo RL. Anti-fungal activity of cathelicidins and their potential role in Candida albicans skin infection. J. Invest. Dermatol. 125(1), 108-115 (2005). (Pubitemid 40981431)
84. Sabetta JR, Depetrillo P, Cipriani RJ, Smardin J, Burns LA, Landry ML. Serum 25-hydroxyvitamin d and the incidence of acute viral respiratory tract infections in healthy adults. PLoS ONE 5(6), E11088 (2010).
85. Urashima M, Segawa T, Okazaki M, Kurihara M, Wada Y, Ida H. Randomized trial of vitamin D supplementation to prevent seasonal influenza A in schoolchildren. Am. J. Clin. Nutr. 91(5), 1255-1260 (2010).
86. Liu PT, Stenger S, Li H et al. Toll-like receptor triggering of a vitamin D-mediated human antimicrobial response. Science 311(5768), 1770-1773 (2006).
87. Wang TT, Nestel FP, Bourdeau V et al. Cutting edge: 1, 25-dihydroxyvitamin D3 is a direct inducer of antimicrobial peptide gene expression. J. Immunol. 173(5), 2909-2912 (2004). (Pubitemid 39141992)
88. Barlow PG, Svoboda P, Mackellar A et al. Antiviral activity and increased host defense against influenza infection elicited by the human cathelicidin LL-37. PLoS ONE 6(10), E25333 (2011).
89. Yasin B, Pang M, Turner JS et al. Evaluation of the inactivation of infectious Herpes simplex virus by host-defense peptides. Eur. J. Clin. Microbiol. Infect. Dis. 19(3), 187-194 (2000). (Pubitemid 30201294)
90. Gordon YJ, Huang LC, Romanowski EG, Yates KA, Proske RJ, Mcdermott AM. Human cathelicidin (LL-37), a multifunctional peptide, is expressed by ocular surface epithelia and has potent antibacterial and antiviral activity. Curr. Eye Res. 30(5), 385-394 (2005). (Pubitemid 40910819)
91. Howell MD, Jones JF, Kisich KO, Streib JE, Gallo RL, Leung DY. Selective killing of vaccinia virus by LL-37: implications for eczema vaccinatum. J. Immunol. 172(3), 1763-1767 (2004). (Pubitemid 38116824)
92. Wang G, Watson KM, Buckheit RW Jr. Anti-human immunodeficiency virus type 1 activities of antimicrobial peptides derived from human and bovine cathelicidins. Antimicrob. Agents Chemother. 52(9), 3438-3440 (2008).
93. Wong JH, Legowska A, Rolka K et al. Effects of cathelicidin and its fragments on three key enzymes of HIV-1. Peptides 32(6), 1117-1122 (2011).
94. Wuerth K, Hancock RE. New insights into cathelicidin modulation of adaptive immunity. Eur. J. Immunol. 41(10), 2817-2819 (2011).
95. Bowdish DM, Davidson DJ, Lau YE, Lee K, Scott MG, Hancock RE. Impact of LL-37 on anti-infective immunity. J. Leukoc. Biol. 77(4), 451-459 (2005). (Pubitemid 40489520)
96. De Y, Chen Q, Schmidt AP et al. LL-37, the neutrophil granule-and epithelial cell-derived cathelicidin, utilizes formyl peptide receptor-like 1 (FPRL1) as a receptor to chemoattract human peripheral blood neutrophils, monocytes, and T cells. J. Exp. Med. 192(7), 1069-1074 (2000).
97. Niyonsaba F, Iwabuchi K, Someya A et al. A cathelicidin family of human antibacterial peptide LL-37 induces mast cell chemotaxis. Immunology 106(1), 20-26 (2002). (Pubitemid 34437873)
98. Niyonsaba F, Someya A, Hirata M, Ogawa H, Nagaoka I. Evaluation of the effects of peptide antibiotics human beta-defensins-1/-2 and LL-37 on histamine release and prostaglandin D (2) production from mast cells. Eur. J. Immunol. 31(4), 1066-1075 (2001).
99. Bowdish DM, Davidson DJ, Speert DP, Hancock RE. The human cationic peptide LL-37 induces activation of the extracellular signal-regulated kinase and p38 kinase pathways in primary human monocytes. J. Immunol. 172(6), 3758-3765 (2004). (Pubitemid 38337960)
100. Mookherjee N, Hamill P, Gardy J et al. Systems biology evaluation of immune responses induced by human host defence peptide LL-37 in mononuclear cells. Mol. Biosyst. 5(5), 483-496 (2009).
101. Elssner A, Duncan M, Gavrilin M, Wewers MD. A novel P2X7 receptor activator, the human cathelicidin-derived peptide LL37, induces IL-1 b processing and release. J. Immunol. 172(8), 4987-4994 (2004). (Pubitemid 38456425)
102. Kin NW, Chen Y, Stefanov EK, Gallo RL, Kearney JF. Cathelin-related antimicrobial peptide differentially regulates T-and B-cell function. Eur. J. Immunol. 41(10), 3006-3016 (2011).
103. Bandholtz L, Ekman GJ, Vilhelmsson M et al. Antimicrobial peptide LL-37 internalized by immature human dendritic cells alters their phenotype. Scand. J. Immunol. 63(6), 410-419 (2006). (Pubitemid 43982195)
104. Davidson DJ, Currie AJ, Reid GS et al. The cationic antimicrobial peptide LL-37 modulates dendritic cell differentiation and dendritic cell-induced T cell polarization. J. Immunol. 172(2), 1146-1156 (2004). (Pubitemid 38113775)
105. Marsh PD, Bradshaw DJ. Dental plaque as a biofilm. J. Ind. Microbiol. 15(3), 169-175 (1995).
106. Rosan B, Lamont RJ. Dental plaque formation. Microbes Infect. 2(13), 1599-1607 (2000).
107. Signat B, Roques C, Poulet P, Duffaut D. Fusobacterium nucleatum in periodontal health and disease. Curr. Issues Mol. Bioll. 13(2), 25-36 (2011).
108. Hell E, Giske CG, Nelson A, Romling U, Marchini G. Human cathelicidin peptide LL37 inhibits both attachment capability and biofilm formation of Staphylococcus epidermidis. Lett. Appl. Microbiol. 50(2), 211-215 (2010).
109. Nelson A, Hultenby K, Hell E et al. Staphylococcus epidermidis isolated from newborn infants express pilus-like structures and are inhibited by the cathelicidin-derived antimicrobial peptide LL37. Pediatr. Res. 66(2), 174-178 (2009).
110. Dean SN, Bishop BM, Van Hoek ML. Natural and synthetic cathelicidin peptides with anti-microbial and anti-biofilm activity against Staphylococcus aureus. BMC Microbiol. 11, 114 (2011). The only paper to demonstrate the capacity of d-LL-37 to inhibit biofilm formation.
111. Prigent-Combaret C, Prensier G, Le Thi TT, Vidal O, Lejeune P, Dorel C. Developmental pathway for biofilm formation in curliproducing Escherichia coli strains: role of flagella, curli and colanic acid. Environ. Microbiol. 2(4), 450-464 (2000). (Pubitemid 33136706)
112. Pawar DM, Rossman ML, Chen J. Role of curli fimbriae in mediating the cells of enterohaemorrhagic Escherichia coli to attach to abiotic surfaces. J. Appl. Microbiol. 99(2), 418-425 (2005). (Pubitemid 41075934)
113. Kikuchi T, Mizunoe Y, Takade A, Naito S, Yoshida S. Curli fibers are required for development of biofilm architecture in Escherichia coli K-12 and enhance bacterial adherence to human uroepithelial cells. Microbiol. Immunol. 49(9), 875-884 (2005). (Pubitemid 41373940)
114. Saldana Z, Xicohtencatl-Cortes J, Avelino F et al. Synergistic role of curli and cellulose in cell adherence and biofilm formation of attaching and effacing Escherichia coli and identification of Fis as a negative regulator of curli. Environ. Microbiol. 11(4), 992-1006 (2009).
115. Overhage J, Campisano A, Bains M, Torfs EC, Rehm BH, Hancock RE. Human host defense peptide LL-37 prevents bacterial biofilm formation. Infect. Immun. 76(9), 4176-4182 (2008). Represents a breakthrough in peptide biofilm research and serves as a proof-of-concept study, demonstrating how LL-37 is able to block both Pseudomonas aeruginosa biofilm growth and accelerate disintegration of preformed biofilms.
116. Dean SN, Bishop BM, Van Hoek ML. Susceptibility of Pseudomonas aeruginosa biofilm to α-helical peptides: D-enantiomer of LL-37. Front. Microbiol. 2, 128 (2011).
117. De La Fuente-Nunez C, Korolik V, Bains M et al. Inhibition of bacterial biofilm formation and swarming motility by a small synthetic cationic peptide. Antimicrob. Agents Chemother. 56(5), 2696-2704 (2012). Aims and succeeds in identifying shorter peptide derivatives that are able to prevent biofilm formation. The peptides are not directly tailored around LL-37 but on a different host defence peptide, thus indicating that the antibiofilm effect at sub-MIC concentrations is a general phenomenon that can likely be found for many of these traditional antimicrobial peptides.
118. O'Toole GA, Kolter R. Flagellar and twitching motility are necessary for Pseudomonas aeruginosa biofilm development. Mol. Microbiol. 30(2), 295-304 (1998). (Pubitemid 28480181)
119. Singh PK, Parsek MR, Greenberg EP, Welsh MJ. A component of innate immunity prevents bacterial biofilm development. Nature 417(6888), 552-555 (2002). (Pubitemid 34595922)
120. Picioreanu C, Kreft JU, Klausen M, Haagensen JA, Tolker-Nielsen T, Molin S. Microbial motility involvement in biofilm structure formation - a 3D modelling study. Water Sci. Technol. 55(8-9), 337-343 (2007). (Pubitemid 46840157)
121. Ganz T. Defensins: antimicrobial peptides of innate immunity. Nat. Rev. Immunol. 3(9), 710-720 (2003). (Pubitemid 41070812)
122. Schittek B, Hipfel R, Sauer B et al. Dermcidin: a novel human antibiotic peptide secreted by sweat glands. Nat. Immunol. 2(12), 1133-1137 (2001). (Pubitemid 33130147)
123. Harder J, Bartels J, Christophers E, Schroder JM. A peptide antibiotic from human skin. Nature 387(6636), 861 (1997).
124. Marchini G, Lindow S, Brismar H et al. The newborn infant is protected by an innate antimicrobial barrier: peptide antibiotics are present in the skin and vernix caseosa. Br. J. Dermatol. 147(6), 1127-1134 (2002). (Pubitemid 36963018)
125. Nizet V, Ohtake T, Lauth X et al. Innate antimicrobial peptide protects the skin from invasive bacterial infection. Nature 414(6862), 454-457 (2001). (Pubitemid 34173727)
126. Braff MH, Hawkins MA, Di Nardo A et al. Structure-function relationships among human cathelicidin peptides: dissociation of antimicrobial properties from host immunostimulatory activities. J. Immunol. 174(7), 4271-4278 (2005). (Pubitemid 40396008)
127. Wang G, Elliott M, Cogen AL, Ezell EL, Gallo RL, Hancock RE. Structure, dynamics, and antimicrobial and immune modulatory activities of human LL-23 and its singleresidue variants mutated on the basis of homologous primate cathelicidins. Biochemistry 51(2), 653-664 (2012).
128. Batoni G, Maisetta G, Brancatisano FL, Esin S, Campa M. Use of antimicrobial peptides against microbial biofilms: advantages and limits. Curr. Med. Chem. 18(2), 256-279 (2011).
129. Moore AJ, Loadman PM, Devine DA, Bibby MC. Extraction of the synthetic lytic peptide, cecropin B, from biological fluid and analysis using reversed-phase high-performance liquid chromatography. J. Chromatogr. B. Biomed. Appl. 672(2), 225-231 (1995).
130. Rozek A, Powers JP, Friedrich CL, Hancock RE. Structure-based design of an indolicidin peptide analogue with increased protease stability. Biochemistry 42(48), 14130-14138 (2003). (Pubitemid 37499409)
131. Bals R, Weiner DJ, Moscioni AD, Meegalla RL, Wilson JM. Augmentation of innate host defense by expression of a cathelicidin antimicrobial peptide. Infect. Immun. 67(11), 6084-6089 (1999). (Pubitemid 29508140)
132. Morgera F, Vaccari L, Antcheva N, Scaini D, Pacor S, Tossi A. Primate cathelicidin orthologues display different structures and membrane interactions. Biochem. J. 417(3), 727-735 (2009).
133. Zelezetsky I, Pontillo A, Puzzi L et al. Evolution of the primate cathelicidin. Correlation between structural variations and antimicrobial activity. J. Biol. Chem. 281(29), 19861-19871 (2006). (Pubitemid 44065759)
134. Wang Y, Agerberth B, Lothgren A, Almstedt A, Johansson J. Apolipoprotein A-I binds and inhibits the human antibacterial/cytotoxic peptide LL-37. J. Biol. Chem. 273(50), 33115-33118 (1998). (Pubitemid 29005678)
135. Tomasinsig L, Pizzirani C, Skerlavaj B et al. The human cathelicidin LL-37 modulates the activities of the P2X7 receptor in a structuredependent manner. J. Biol. Chem. 283(45), 30471-30481 (2008).
136. Sorensen O, Bratt T, Johnsen AH, Madsen MT, Borregaard N. The human antibacterial cathelicidin, hCAP-18, is bound to lipoproteins in plasma. J. Biol. Chem. 274(32), 22445-22451 (1999).
137. Bessalle R, Kapitkovsky A, Gorea A, Shalit I, Fridkin M. All-D-magainin: chirality, antimicrobial activity and proteolytic resistance. FEBS Lett. 274(1-2), 151-155 (1990). (Pubitemid 20378143)
138. Hong SY, Oh JE, Lee KH. Effect of d-amino acid substitution on the stability, the secondary structure, and the activity of membrane-active peptide. Biochem. Pharmacol. 58(11), 1775-1780 (1999). (Pubitemid 29505418)
139. Godballe T, Nilsson LL, Petersen PD, Jenssen H. Antimicrobial b-peptides and α-peptoids. Chem. Biol. Drug Des. 77(2), 107-116 (2011).
140. Chongsiriwatana NP, Patch JA, Czyzewski AM et al. Peptoids that mimic the structure, function, and mechanism of helical antimicrobial peptides. Proc. Natl Acad. Sci. USA 105(8), 2794-2799 (2008). (Pubitemid 351723623)
141. Kapoor R, Wadman MW, Dohm MT, Czyzewski AM, Spormann AM, Barron AE. Antimicrobial peptoids are effective against Pseudomonas aeruginosa biofilms. Antimicrob. Agents Chemother. 55(6), 3054-3057 (2011).
142. Gabriel M, Nazmi K, Veerman EC, Nieuw Amerongen AV, Zentner A. Preparation of LL-37-grafted titanium surfaces with bactericidal activity. Bioconjug. Chem. 17(2), 548-550 (2006).
143. Shaykhiev R, Beisswenger C, Kandler K et al. Human endogenous antibiotic LL-37 stimulates airway epithelial cell proliferation and wound closure. Am. J. Physiol. Lung Cell Mol. Physiol. 289(5), L842-L848 (2005). (Pubitemid 41504416)
144. Peyrot M, Rubin RR. Patient-reported outcomes in adults with Type 2 diabetes using mealtime inhaled technosphere insulin and basal insulin versus premixed insulin. Diabetes Technol. Ther. 13(12), 1201-1206 (2011).
145. Pompilio A, Scocchi M, Pomponio S et al. Antibacterial and anti-biofilm effects of cathelicidin peptides against pathogens isolated from cystic fibrosis patients. Peptides 32(9), 1807-1814 (2011).
146. Chan C, Burrows LL, Deber CM. Helix induction in antimicrobial peptides by alginate in biofilms. J. Biol. Chem. 279(37), 38749-38754 (2004). (Pubitemid 39296032)
147. Bals R, Weiner DJ, Meegalla RL, Wilson JM. Transfer of a cathelicidin peptide antibiotic gene restores bacterial killing in a cystic fibrosis xenograft model. J. Clin. Invest. 103(8), 1113-1117 (1999). (Pubitemid 29207244)
148. Li Y, Li X, Wang G. On-resin cleavage of bacterially expressed fusion proteins for purification of active recombinant peptides SK-29, KR-20, LL-29, and LL-23 from human sweat or skin. Protein Exp. Purif. 55(2), 395-405 (2007). (Pubitemid 47376882)
149. Mohanty S, Mishra S, Jena P, Jacob B, Sarkar B, Sonawane A. An investigation on the antibacterial, cytotoxic and antibiofilm efficacy of starch-stabilized silver nanoparticles. Nanomedicine 8(6), 916-924 (2012).